• PARP1/FAK/COL5A1 Axis Drives EMT in Cholesterol-Resistant Ov

  2026-07-17

  This study uncovers a novel oncogenic signaling circuit in cholesterol-resistant ovarian cancer, demonstrating that persistent high cholesterol levels activate the PARP1/FAK/COL5A1 axis to promote epithelial-mesenchymal transition (EMT) and tumor progression. The findings highlight mechanistic intervention points for disrupting metastasis and provide actionable insights for advanced cancer biology research.

• WNT5a/GSK3/β-catenin Axis Controls FAP Adipogenesis in Muscl

  2026-07-17

  This study reveals that the WNT5a/GSK3/β-catenin axis is a critical regulator of adipogenesis in skeletal muscle fibro/adipogenic progenitors (FAPs). By dissecting signaling dynamics with high-dimensional tools, the research uncovers therapeutic opportunities for modulating muscle degeneration and offers mechanistic insights vital for muscle, stem cell, and Wnt pathway research.

• Chlorpromazine Hydrochloride in Antipsychotic Research Workf

  2026-07-16

  Chlorpromazine hydrochloride is a benchmark tool for dissecting dopamine receptor signaling and antiemetic pathways in CNS and nanomedicine research. This article details robust experimental workflows, protocol parameters, and troubleshooting strategies that leverage APExBIO’s high-purity chlorpromazine for reproducible, data-driven results.

• Midecamycin: Mechanistic Leverage in Modern Translational Re

  2026-07-16

  This article analyzes midecamycin’s role as a pivotal acetoxy-substituted macrolide antibiotic, unpacking its unique mechanism of bacterial protein synthesis inhibition and strategic applications in translational research. We synthesize recent molecular insights, resistance mechanisms, and protocol optimization, offering actionable guidance for microbiology and antibiotic resistance studies. APExBIO's midecamycin (BA1041) is spotlighted as a rigorous and versatile research-use-only tool. The discussion bridges foundational mechanism, emerging resistance threats, and workflow innovation—empowering investigators to navigate and shape the evolving antibacterial landscape.

• Octyl-α-ketoglutarate: Enhancing Prolyl Hydroxylase Substrat

  2026-07-15

  Octyl-α-ketoglutarate stands out as a cell-permeable prolyl hydroxylase substrate, enabling precise manipulation of α-KG-dependent hypoxia signaling in metabolic research. Its rapid uptake and ability to restore HIF-1α regulation in TCA cycle–dysfunctional models make it indispensable for cancer metabolism studies—especially those interrogating IDH mutations and metabolic reprogramming.

• CUDC-907: Practical Protocols for Dual PI3K and HDAC Inhibit

  2026-07-15

  CUDC-907 is a dual PI3K and HDAC inhibitor designed for in vitro cancer research requiring simultaneous modulation of PI3K/AKT and histone deacetylase pathways. It is not validated for clinical or diagnostic use and must be handled with precise laboratory protocols to ensure reproducibility and data integrity.

• Novel Allosteric Inhibitors Target PDK4 in Metabolic Disease

  2026-07-14

  This article reviews the discovery and characterization of a new class of selective allosteric inhibitors of pyruvate dehydrogenase kinase 4 (PDK4), highlighting compound 8c's nanomolar potency and therapeutic efficacy in metabolic, allergic, and cancer models. The work advances our understanding of mitochondrial energy metabolism modulation and provides new scaffolds for developing PDK4-targeted therapies.

• DRB as a Precision Tool: Guiding Cell Fate via CDK and RNA R

  2026-07-14

  Explore how 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) enables precision control of cell fate through targeted inhibition of CDKs and RNA polymerase II. This article uniquely connects DRB's mechanistic actions to practical assay design and advances in stem cell transition research.

• YAP-TEAD and PPARα Crosstalk in WY-14643-Induced Liver Regen

  2026-07-13

  This study uncovers that the YAP-TEAD transcriptional module is essential for PPARα-driven hepatomegaly and liver regeneration in mice. Using genetic and pharmacological models, the authors demonstrate that WY-14643 (Pirinixic Acid)–mediated PPARα activation triggers liver growth via a YAP-dependent mechanism, providing new mechanistic insight for metabolic disorder and regenerative medicine research.

• Toremifene in Breast Cancer: Insights from 20 Years of Data

  2026-07-13

  This review synthesizes two decades of clinical data on toremifene, a selective estrogen receptor modulator (SERM), for breast cancer therapy. It highlights the evolution of biomarker-driven treatment, the comparative pharmacologic landscape, and the implications for personalized endocrine strategies.

• PDK4-IN-1 Hydrochloride: Optimizing PDH Activation Workflows

  2026-07-12

  PDK4-IN-1 hydrochloride is a next-generation, nanomolar-potency pyruvate dehydrogenase kinase 4 inhibitor that redefines metabolic modulation in both in vitro and in vivo research. This guide provides actionable workflows, troubleshooting insights, and real-world use-cases, empowering metabolic, cardiac, and tumor studies to leverage the selectivity and stability of APExBIO's flagship compound.

• Targeted SPP1 Inhibition in TAMs Reduces Tumor Growth

  2026-07-10

  Kartal et al. introduce a phenotypic screening approach to identify and deliver small molecule inhibitors that downregulate SPP1 in tumor-associated macrophages (TAMs), leading to significant tumor regression in preclinical models. This work provides a mechanistically distinct strategy for reprogramming the tumor microenvironment and opens new avenues for cancer immunotherapy research.

• Verapamil ((±)-Verapamil): Mechanistic Insights in Hypoxia-D

  2026-07-09

  Explore the advanced mechanisms of Verapamil ((±)-Verapamil) as a P-glycoprotein inhibitor in hypoxia-driven inflammation models. This article uncovers distinct molecular pathways and practical assay guidance for researchers.

• Gepotidacin (GSK2140944): Transforming Antibacterial Researc

  2026-07-09

  Gepotidacin, a first-in-class triazaacenaphthylene antibiotic, enables researchers to directly interrogate bacterial DNA replication pathways and overcome resistance in multidrug-resistant strains. This guide details actionable protocols, troubleshooting insights, and comparative advantages to empower antibacterial research with APExBIO’s Gepotidacin.

• Biotin-azide: Enabling Quantitative Interactome Mapping by C

  2026-07-08

  Explore how Biotin-azide empowers precision bio-orthogonal chemical labeling and quantitative interactome mapping in complex lipid-signaling research. This article reveals mechanistic insights, protocol strategies, and advanced assay considerations for next-generation molecular biology.

15317 records 1/1022 page Next 12345 下5页 Last page